November 2015

Results from the ELIXA trial were presented in June at the 75th Scientific Sessions of the American Diabetes Association.

The algorithm-driven system in the study was a step up from the improved technology that has reached the market in recent years, providing more consistent glucose control.

The weeks leading up to the release of the Dietary Guidelines for Americans have seen a series of reports on what kinds of diets work and attacks on the work that went into the report that informs the nation's nutrition policy.

A newly approved therapy offers the first new option in years to prevent hyperkalemia.

An Interview with Joslin's George King, MD

This commentary was adapted from an appearance by the authors at Patient-Centered Diabetes Care, a conference jointly presented by The American Journal of Managed Care and Joslin Diabetes Center.

Research at the University of Tennessee Health Sciences could lead to human trials in the next 2 to 3 years.

Several clinical trials under way are examining whether a new class of therapy approved to treat type 2 diabetes can also treat type 1.

A partnership between JDRF and Janssen Pharmaceuticals seeks ways to intercept the disease before it progresses.

Employer policies for access to maximum benefits do not always match those for access to obesity therapy.

The nation's largest pharmacy benefits manager has presumably negotiated discounts to cover both cholesterol-lowering drugs.

Sanofi's vice president of Diabetes Integrated Care discusses the recent collaboration with Google.